NCT00290433 - Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Lymphoma

Interventions

DRUG

Cyclophosphamide

Cycle 1: 300 mg/m\^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.

DRUG

Mesna

Cycle 1: 600 mg/m\^2 by vein Continuous Infusion Over Days 1, 2, and 3.

DRUG

Vincristine

Cycle 1: 1.4 mg/m\^2 by vein On Day 4 and 11.

DRUG

Methotrexate

Cycle 1 and 2: 200 mg/m\^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m\^2 IV Over 22 Hours on Day 1.

DRUG

Ara-C

Cycle 1 and 2: 3 Gm/m\^2 Over 2 Hours Twice Daily On Days 2 and 3.

DRUG

Dexamethasone

Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.

DRUG

G-CSF

Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.

DRUG

Doxil

Cycle 1: 25 mg/m\^2 by vein Over 1 Hour on Day 2.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston